A PHASE 1 PLACEBO-CONTROLLED DOSE-ESCALATION SAFETY AND PHARMACOKINETIC STUDY OF IN-007, A NEBULIZED, PAN-S…
Award details are derived from public USAspending.gov records. Not a bid recommendation.
Award details
- Award ID
- HT942525CE039
- Contractor
- INHALON BIOPHARMA, INC.
- Awarding agency
- Department of Defense
- Sub-agency / office
- Defense Health Agency
- Award amount
- $3,175,643
- Period of performance
- Sep 22, 2025 – Dec 31, 2027
- NAICS
- 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Place of performance
- MORRISVILLE, NC, 275608425, USA
- Competition
- FULL AND OPEN COMPETITION · Set-aside: NO SET ASIDE USED. · 44 offers
- Pricing
- FIXED PRICE LEVEL OF EFFORT
- Financial breakdown
- Current value $3,175,643 · Obligated $3,175,643 · Potential value $3,175,643 · Latest action obligation $3,175,643
Public award description
A PHASE 1 PLACEBO-CONTROLLED DOSE-ESCALATION SAFETY AND PHARMACOKINETIC STUDY OF IN-007, A NEBULIZED, PAN-SARS ACE2-DECOY THERAPEUTIC FOR PANDEMIC PREPAREDNESS
Find out who's winning similar federal contracts
Discover comparable awards, related contractors, and agency purchasing history.
Related intelligence
- Agency: Department of Defense
- PSC AN13 — Product Service Code AN13
- Federal market intelligence software